<p>康寶萊的股價在今年經歷了強勁的牛市突破，從三月份的低點 5 美元上漲至目前的 14 美元，市值超過 14 億美元。那麼，HLF 的股價在未來一年是否會繼續強勁反彈呢？</p>
<p><strong>康寶萊股價在其穩健增長中獲得動力</strong></p>
<p>康寶萊是健康和保健行業的頂尖公司，主要專注於在美國及其他國家的直銷。</p>
<p>該公司的業務一直備受爭議，但在過去幾個月中表現相對良好，因為其產品的需求持續上升。</p>
<p>其最新的業績顯示，北美業務自 2021 年第二季度以來首次恢復增長，顯示出需求的韌性。同時，網絡中分銷商的數量在大多數地區也有所增加。</p>
<p>關鍵的拉丁美洲業務繼續蓬勃發展，銷售額增長了 11%，達到 2.29 億美元。其 EMEA 和亞太地區的業務分別增長了 2% 和 3%。</p>
<p>該季度收入增長了 2.7%，達到 13 億美元，而備受關注的息税折舊攤銷前利潤（EBITDA）則上升至 1.63 億美元。</p>
<p>與此同時，公司通過償還 1.47 億美元的未償票據繼續改善其資產負債表，並將總槓桿比率降低至 2.8 倍。</p>
<p><strong>分析師對公司的轉機持樂觀態度</strong></p>
<p>華爾街分析師對公司未來幾周的收入增長持樂觀態度。跟蹤該公司的三位分析師的平均估計是，本季度收入將達到 12.5 億美元，比去年增長 3.38%。</p>
<p>其年度收入預估 modest 增加 0.20%，達到 50 億美元，預計明年將達到 51.2 億美元。他們還預計今年每股收益將達到 2.15 美元，明年將達到 2.75 美元。</p>
<p>還有跡象表明，該公司已被嚴重低估，其前瞻市盈率已降至 7.6，遠低於行業中位數 18.8 和其五年平均值 9。</p>
<p>同樣，該公司的前瞻企業價值與息税折舊攤銷前利潤（EV-to-EBITDA）倍數為 5.43，也遠低於行業中位數 10.3，且低於其歷史平均水平。</p>
<p>隨着投資者押注於其轉型戰略，康寶萊的股價也大幅上漲，該戰略包括更多產品發佈、數字化轉型（包括 Pro2col 應用程序向近 8000 名分銷商的推出）、利潤優化和減債。</p>
<p><strong>康寶萊股價技術分析</strong></p>
<p>周線圖顯示，隨着公司轉型的持續，HLF 股價在過去幾個月中反彈。它已經突破了 50 周和 100 周的指數移動平均線（EMA）。</p>
<p>該股也接近 23.6% 的斐波那契回撤位 18 美元。同時，它形成了一個反向頭肩形態，而相對強弱指數（RSI）和隨機振盪器均指向上方。</p>
<p>因此，最可能的情景是 HLF 股價將繼續上漲，牛市目標為 23.6% 的回撤位 18 美元。這個價格目標比當前水平高出約 25%。</p>

康寶萊

<p>康寶萊的股價從 5 美元飆升至 14 美元，市值提升至 14 億美元。分析師對持續的收入增長和被低估持樂觀態度，預計未來市盈率為 7.6。技術分析顯示進一步上漲的潛力，目標價為 18 美元，受到積極的相對強弱指數（RSI）和隨機振盪器（Stochastic Oscillator）趨勢的支持</p>

<p>The Herbalife stock price staged a strong bullish breakout this year, moving from a low of $5 in March to the current $14, pushing its market capitalization to over $1.4 billion. So, will the HLF share price continue its strong rebound in the coming year?</p>
<div class="lb-trans"><p>康寶萊的股價在今年經歷了強勁的牛市突破，從三月份的低點 5 美元上漲至目前的 14 美元，市值超過 14 億美元。那麼，HLF 的股價在未來一年是否會繼續強勁反彈呢？</p>
</div><p><strong>Herbalife stock price gains steam amid its resilient growth</strong></p>
<div class="lb-trans"><p><strong>康寶萊股價在其穩健增長中獲得動力</strong></p>
</div><p>Herbalife is a top company in the health and wellness industries, focusing mostly on direct selling in the United States and other countries.</p>
<div class="lb-trans"><p>康寶萊是健康和保健行業的頂尖公司，主要專注於在美國及其他國家的直銷。</p>
</div><p>The company’s business, which has always been highly controversial, has done relatively well in the past few months as demand for its products has continued rising.</p>
<div class="lb-trans"><p>該公司的業務一直備受爭議，但在過去幾個月中表現相對良好，因為其產品的需求持續上升。</p>
</div><p>Its most recent results showed that its North American business returned to growth for the first time since the second quarter of 2021, a sign of resilient demand. It also jumped as the number of distributors in its network jumped in most of its regions.</p>
<div class="lb-trans"><p>其最新的業績顯示，北美業務自 2021 年第二季度以來首次恢復增長，顯示出需求的韌性。同時，網絡中分銷商的數量在大多數地區也有所增加。</p>
</div><p>The crucial Latin American business continued to thrive, with its sales rising by 11% to $229 million. Its EMEA and Asia Pacific businesses grew by 2% and 3%, respectively.</p>
<div class="lb-trans"><p>關鍵的拉丁美洲業務繼續蓬勃發展，銷售額增長了 11%，達到 2.29 億美元。其 EMEA 和亞太地區的業務分別增長了 2% 和 3%。</p>
</div><p>The revenue rose by 2.7% in the quarter to $1.3 billion, while the closely-watched earnings before interest, tax, depreciation, and amortization rose to $163 million.</p>
<div class="lb-trans"><p>該季度收入增長了 2.7%，達到 13 億美元，而備受關注的息税折舊攤銷前利潤（EBITDA）則上升至 1.63 億美元。</p>
</div><p>Meanwhile, the company continued to improve its balance sheet by repaying the $147 million in outstanding notes and then reduced the total leverage ratio to 2.8x.</p>
<div class="lb-trans"><p>與此同時，公司通過償還 1.47 億美元的未償票據繼續改善其資產負債表，並將總槓桿比率降低至 2.8 倍。</p>
</div><p><strong>Analysts are optimistic about the company’s turnaround</strong></p>
<div class="lb-trans"><p><strong>分析師對公司的轉機持樂觀態度</strong></p>
</div><p>Wall Street analysts are optimistic that the company’s revenue growth will continue in the coming weeks. The average estimate among the three analysts tracking the company is that its revenue will be $1.25 billion this quarter, up by 3.38% from what it made last year.</p>
<div class="lb-trans"><p>華爾街分析師對公司未來幾周的收入增長持樂觀態度。跟蹤該公司的三位分析師的平均估計是，本季度收入將達到 12.5 億美元，比去年增長 3.38%。</p>
</div><p>Its annual revenue estimate is a modest 0.20% increase to $5 billion, followed by $5.12 billion in the coming year. They also expect that its earnings-per-share will move to $2.15 this year and $2.75 in the coming year.</p>
<div class="lb-trans"><p>其年度收入預估 modest 增加 0.20%，達到 50 億美元，預計明年將達到 51.2 億美元。他們還預計今年每股收益將達到 2.15 美元，明年將達到 2.75 美元。</p>
</div><p>There are also signs that the company has become highly undervalued as its forward price-to-earnings ratio has moved to 7.6, much lower than the sector median of 18.8 and its five-year average of 9.</p>
<div class="lb-trans"><p>還有跡象表明，該公司已被嚴重低估，其前瞻市盈率已降至 7.6，遠低於行業中位數 18.8 和其五年平均值 9。</p>
</div><p>Similarly, the company’s forward EV-to-EBITDA multiple of 5.43 is also much lower than the sector median of 10.3, also much lower than its historical averages.</p>
<div class="lb-trans"><p>同樣，該公司的前瞻企業價值與息税折舊攤銷前利潤（EV-to-EBITDA）倍數為 5.43，也遠低於行業中位數 10.3，且低於其歷史平均水平。</p>
</div><p>The Herbalife stock price has also jumped as investors bet on its turnaround strategy, which includes more product launches, digital transformation, including the Pro2col app rollout to nearly 8,000 distributors, margin optimization, and debt reduction.</p>
<div class="lb-trans"><p>隨着投資者押注於其轉型戰略，康寶萊的股價也大幅上漲，該戰略包括更多產品發佈、數字化轉型（包括 Pro2col 應用程序向近 8000 名分銷商的推出）、利潤優化和減債。</p>
</div><p><strong>Herbalife share price technical analysis</strong></p>
<div class="lb-trans"><p><strong>康寶萊股價技術分析</strong></p>
</div><p>The weekly chart shows that the HLF stock price has rebounded in the past few months as the company’s turnaround continued. It has already moved above the 50-week and 100-week Exponential Moving Averages (EMA).</p>
<div class="lb-trans"><p>周線圖顯示，隨着公司轉型的持續，HLF 股價在過去幾個月中反彈。它已經突破了 50 周和 100 周的指數移動平均線（EMA）。</p>
</div><p>The stock is also nearing the 23.6% Fibonacci Retracement level at $18. It also formed an inverse head-and-shoulders pattern, while the Relative Strength Index (RSI) and the Stochastic Oscillator have all pointed upwards.</p>
<div class="lb-trans"><p>該股也接近 23.6% 的斐波那契回撤位 18 美元。同時，它形成了一個反向頭肩形態，而相對強弱指數（RSI）和隨機振盪器均指向上方。</p>
</div><p>Therefore, the most likely scenario is where the HLF stock will continue rising as bulls target the 23.6% retracement level at $18. This price target is about 25% above the current level.</p>
<div class="lb-trans"><p>因此，最可能的情景是 HLF 股價將繼續上漲，牛市目標為 23.6% 的回撤位 18 美元。這個價格目標比當前水平高出約 25%。</p>
</div>

康寶萊的股票價格在 2025 年出現反彈：這種漲勢會持續嗎？